Evidence map›Paper›PMID 36632055›Full record

ArticleClinical and translational radiation oncology2023

On the sensitivity of PROMs during breast radiotherapy.

Gerd Heilemann, Andreas Renner, Daniela Kauer-Dorner, Stefan Konrad, Inga-Malin Simek, Dietmar Georg, Joachim Widder

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Gerd HeilemannDepartment of Radiation Oncology, Comprehensive Cancer Center Vienna, Medical University Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Andreas RennerDepartment of Radiation Oncology, Comprehensive Cancer Center Vienna, Medical University Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Daniela Kauer-DornerDepartment of Radiation Oncology, Comprehensive Cancer Center Vienna, Medical University Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Stefan KonradDepartment of Radiation Oncology, Comprehensive Cancer Center Vienna, Medical University Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Inga-Malin SimekDepartment of Radiation Oncology, Comprehensive Cancer Center Vienna, Medical University Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Dietmar GeorgDepartment of Radiation Oncology, Comprehensive Cancer Center Vienna, Medical University Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Joachim WidderDepartment of Radiation Oncology, Comprehensive Cancer Center Vienna, Medical University Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Comprehensive Cancer Center Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To investigate the sensitivity of patient-reported outcome measures (PROMs) to detect treatment-related side effects in patients with breast cancer undergoing external beam photon radiotherapy. Methods: As part of daily clinical care, an in-house developed PROM tool was used to assess side effects in patients during a) whole-breast irradiation (WBI) to 40 Gy, b) WBI with a sequential boost of 10 Gy, and c) partial-breast irradiation (PBI) to 40 Gy. Results: 414 patients participated in this prospective study between October 2020 and January 2022, with 128 patients (31 %) receiving WBI, 241 (58 %) receiving WBI followed by a sequential boost, and 50 patients (12 %) receiving PBI. Significant differences in the reported toxicities (itching, radiation skin reaction, skin darkening, and tenderness and swelling) were reported between the WBI cohorts with and without boost (p < 0.001, p < 0.001, p < 0.001, and p = 0.002, respectively). The comparison of PBI with WBI (no-boost) yielded significant differences for radiation skin reaction (p < 0.001). Conclusion: The results highlight the high sensitivity of PROMs to detect treatment-related side effects in patients with breast cancer. Thus, PROMs may be a valuable tool for quality control and may support evidence-based learning from real-world data originating from daily routine care.

Indexed as

Breast cancereHealthIrradiationPartial breastPatient reported outcome measuresQuality of life

Identifiers

PMID36632055
PMCPMC9827355
OpenAlexW4312221830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.